Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online May 1, 2002.
Copyright & Usage
THE JOURNAL OF NUCLEAR MEDICINE
Author Information
- Christian Waldherr, MD1,
- Miklos Pless, MD2,
- Helmut R. Maecke, PhD3,
- Tilmann Schumacher, MD1,
- Armin Crazzolara, MD1,
- Egbert U. Nitzsche, MD1,
- Andreas Haldemann, MD4 and
- Jan Mueller-Brand, MD1
- 1PET Center, Institute of Nuclear Medicine, University Hospital, University of Basel, Basel, Switzerland
- 2Department of Oncology, University Hospital, University of Basel, Basel, Switzerland
- 3Institute of Radiological Chemistry, University Hospital, University of Basel, Basel, Switzerland
- 4Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis
- Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
- NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
- Recombinant {alpha}1-Microglobulin Is a Potential Kidney Protector in 177Lu-Octreotate Treatment of Neuroendocrine Tumors
- Somatostatin Receptor 2-Targeting Compounds
- Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy
- Metastatic Insulinoma: Current Molecular and Cytotoxic Therapeutic Approaches for Metastatic Well-Differentiated panNETs
- Somatostatin Receptor-Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial
- Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors
- GEP-NETS UPDATE: Radionuclide therapy in neuroendocrine tumors
- PRRT: Defining the Paradigm Shift to Achieve Standardization and Individualization
- Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging
- Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- Molecular radiotherapy
- Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
- A New Era for the Systemic Therapy of Neuroendocrine Tumors
- Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro
- Radiopeptide Imaging and Therapy in Europe
- Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin
- 177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma
- Altered Biodistribution of Somatostatin Analogues After First Cycle of Peptide Receptor Radionuclide Therapy
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
- Targeted Therapy in Advanced Well-Differentiated Neuroendocrine Tumors
- 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors
- In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy
- Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study
- Treatment of Metastatic Carcinoid Tumors With Radiolabeled Biologic Molecules
- Carcinoid Tumors
- MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors
- Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial
- [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma
- Gastrointestinal neuroendocrine tumors: a role for targeted therapies?
- GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
- [Lys40(Ahx-DTPA-111In)NH2]Exendin-4, a Very Promising Ligand for Glucagon-like Peptide-1 (GLP-1) Receptor Targeting
- Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma
- Dosimetry in Peptide Radionuclide Receptor Therapy: A Review
- 177Lu-AMBA: Synthesis and Characterization of a Selective 177Lu-Labeled GRP-R Agonist for Systemic Radiotherapy of Prostate Cancer
- Anticancer Activity of Targeted Proapoptotic Peptides
- Oral Versus Intravenous Administration of Lysine: Equal Effectiveness in Reduction of Renal Uptake of [111In-DTPA]Octreotide
- Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
- Megalin Is Essential for Renal Proximal Tubule Reabsorption of 111In-DTPA-Octreotide
- Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization?
- Treatment with 177Lu-DOTATOC of Patients with Relapse of Neuroendocrine Tumors After Treatment with 90Y-DOTATOC
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
- Practical Dosimetry of Peptide Receptor Radionuclide Therapy with 90Y-Labeled Somatostatin Analogs
- Peptide Receptor Radionuclide Therapy for Non-Radioiodine-Avid Differentiated Thyroid Carcinoma
- A New Prostate Carcinoma Binding Peptide (DUP-1) for Tumor Imaging and Therapy
- Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs
- Long-Term Follow-Up of Renal Function After Peptide Receptor Radiation Therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0, Tyr3-Octreotate
- Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship
- 68Ga-Labeled Peptides in Tumor Imaging
- Therapeutic Efficacy of a 188Re-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptide Analog in Murine and Human Melanoma-Bearing Mouse Models
- Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs
- High Expression of Neuropeptide Y Receptors in Tumors of the Human Adrenal Gland and Extra-Adrenal Paraganglia
- Radiation Therapy of Small Cell Lung Cancer with 177Lu-DOTA-Tyr3-Octreotate in an Animal Model
- Inhomogeneous Localization of Radioactivity in the Human Kidney After Injection of [111In-DTPA]Octreotide
- Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [177Lu-DOTA0,Tyr3]octreotate
- A Stylized Computational Model of the Rat for Organ Dosimetry in Support of Preclinical Evaluations of Peptide Receptor Radionuclide Therapy with 90Y, 111In, or 177Lu
- Evaluating the Clinical Effectiveness of 90Y-SMT 487 in Patients with Neuroendocrine Tumors
- New Advances in Peptide Receptor Radionuclide Therapy